Pioglitazone and cardiovascular risk. A comprehensive meta‐analysis of randomized clinical trials
- 29 October 2008
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 10 (12) , 1221-1238
Abstract
Aim: The aim of this meta‐analysis of randomized clinical trials (RCT) was to assess whether pioglitazone is also associated with increased cardiovascular risk, as recently reported for rosiglitazone. Methods: RCT of pioglitazone were retrieved from Medline (any date up to 31 August 2007; English language only). Unpublished RCT were identified through http://www.clinicaltrials.gov or http://www.fda.gov websites, and results on cardiovascular outcomes were retrieved from investigators and/or sponsors, whenever possible. RCT were included in meta‐analysis if pioglitazone was compared with other treatments (placebo, active comparators or no treatment) for at least 4 weeks. Ninety‐four trials, 10 of which were unpublished, were retrieved; those included in the analysis, which excluded PROspective PioglitAzone Clinical Trial In MacroVascular Events (PROACTIVE), enrolled 11 268 and 9912 patients in the pioglitazone and comparator groups respectively. Data for analysis, extracted independently by two observers, included all‐cause and cardiovascular mortality and incidence of non‐fatal coronary events and heart failure. Proportions of outcome measures across treatment groups were compared by odds ratios (ORs) and 95% confidence interval. Results: Pioglitazone was associated with reduced all‐cause mortality [OR 0.30 (0.14–0.63); p < 0.05], with no relevant effect on non‐fatal coronary events. The observed increase in incidence of non‐fatal heart failure was not statistically significant [OR 1.38 (0.90–2.12)]. Conclusion: The use of pioglitazone does not appear to be harmful in terms of cardiovascular events and all‐cause deaths.Keywords
This publication has 103 references indexed in Scilit:
- Effects of Growth Hormone and Pioglitazone in Viscerally Obese Adults with Impaired Glucose Tolerance: A Factorial Clinical TrialPLoS Clinical Trials, 2007
- The Effect of β-Adrenergic and Peroxisome Proliferator–Activated Receptor-γ Stimulation on Target Genes Related to Lipid Metabolism in Human Subcutaneous Adipose TissueDiabetes Care, 2007
- Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndromeAmerican Heart Journal, 2007
- Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitusAmerican Heart Journal, 2006
- Pioglitazone as adjunctive therapy in adolescents with type 1 diabetesThe Journal of Pediatrics, 2006
- Effect of Rosiglitazone on Endothelial Function and Inflammatory Markers in Patients With the Metabolic SyndromeDiabetes Care, 2006
- Pilot trial: Pioglitazone versus placebo in patients with plaque psoriasis (the P6)International Journal of Dermatology, 2005
- What to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse dataStatistics in Medicine, 2004
- Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning studyAmerican Heart Journal, 2003
- Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by PioglitazoneBiochemical and Biophysical Research Communications, 2000